Argentina Narrows Remediar Essential Medicines List to Vascular Drugs

Resolution 1447/2026 replaces the 2021 primary-care essential medicines list behind Argentina’s Remediar programme with a list focused on vascular disease, leaving other conditions to provincial procurement after a transition kit through end-2026.

A conveyor belt carrying many plain boxes is stopped by a closed gate, with exactly six boxes having passed through a narrow side slot onto an empty platform beyond, while faceless silhouettes stand beside the accumulated pile and a tall obelisk silhouette rises in the background.

MARKET ACCESS · ESSENTIAL MEDICINES POLICY · OCTOBER 31, 2026 · ARGENTINA

Vascular disease now defines the boundary of Argentina’s national essential medicines commitment at the primary-care level. Resolution 1447/2026, signed by the Ministerio de Salud de la Nación (Argentina’s federal health ministry) on 14 October 2026 and published in the Official Gazette on 15 October 2026, repeals the 2021 essential medicines list that underpinned the Remediar programme and replaces it with a list for the prevention and treatment of vascular diseases, according to the resolution’s text.

The legal instrument frames the change as an alignment with the Plan Nacional de Salud Vascular 2026-2030 (National Vascular Health Plan 2026-2030), approved by Resolution 1445/2026 on the same date. The resolution’s preamble cites Law 25.501, which declared cardiovascular disease prevention a national priority. In its 20 October communiqué, as reported by Perfil, the ministry argued that vascular diseases are the country’s leading cause of death and that acting on hypertension and cholesterol prevents avoidable events.

14.1M

The Instituto de Efectividad Clínica y Sanitaria (IECS) recorded 14.1 million treatments dispensed under Remediar in 2025, down from 29.8 million in 2023, per its June 2026 report cited by Perfil.

From a broad basket to a vascular list

According to Perfil, Nicolás Kreplak, the health minister of Buenos Aires province, stated on the social platform X that the government had replaced a list of 128 medicines with six. Pablo Yedlin, a national deputy, described the change as the ‘death of the Remediar programme’ and warned that medicines for children, adolescents, pregnant people and adults without cardiovascular disease would fall outside national responsibility, per Perfil’s reporting.

The ministry’s position, as relayed by Perfil, is that the reorganisation ‘seeks to administer limited resources and does not imply the closure of Remediar.’ A transition kit will be sent to provinces through the end of 2026 so that jurisdictions can organise their own procurement for conditions no longer covered nationally. The ministry also announced improvements in traceability, stating that fewer than 10% of primary-care centres had been reporting the destination of medicine kits, per Perfil.

The volume trajectory of the programme adds context. The Instituto de Efectividad Clínica y Sanitaria (IECS), an Argentine health-policy research institute, recorded in a June 2026 report — issued before the resolution — that treatments dispensed under Remediar fell from 29.8 million in 2023 to 14.1 million in 2025, per Perfil’s citation of that report. The same report described the prior basket as 75 active ingredients in 99 presentations, distributed according to the epidemiological profile of each jurisdiction. That territorial calibration is precisely what the ministry’s communiqué cited as a deficiency of the prior scheme — a contradiction at the centre of the reform’s contested rationale.

Provincial capacity and the access gap risk

The structural risk in the redesign is fiscal and administrative heterogeneity. The IECS report, cited by Perfil, found that provincial responses to prior supply shortfalls were uneven, and warned that differences in fiscal capacity and management could deepen access gaps. The implication — which the IECS framed as a risk, not a finding — is that a patient’s place of residence may increasingly determine whether treatment continuity is maintained for conditions outside the national vascular list.

The transition kit gives the change a defined horizon: the end of 2026, after which provinces carry procurement for the conditions that left the national list. For generic manufacturers that supplied national Remediar tenders, the likely operational consequence is a shift from a single centralised buyer to provincial procurement processes, each with its own budget cycle and administrative capacity — a fragmentation that may be associated with higher transaction costs and less predictable volumes.

What to Watch

  1. Whether provincial health ministries set up procurement mechanisms for the conditions exiting national coverage before the end-2026 transition deadline.
  2. Follow-up data from the IECS or a similar body on treatments dispensed in 2027, the first test of whether provincial procurement compensates for the national contraction.
  3. Any legal or parliamentary challenge to Resolution 1447/2026, given the public objections from Kreplak and Yedlin reported by Perfil.
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

The deeper analytical point is one of sequencing. The ministry’s rationale rests on the premise that concentrating national resources on vascular prevention — the leading cause of mortality — is a better use of limited procurement capacity than a broad list with low traceability. That logic is defensible in isolation. Its weakness is that it assumes provincial systems can absorb the residual demand with a single transition kit as the bridge. The IECS data showing a halving of dispensed treatments between 2023 and 2025 — before the resolution — suggests the system was already under strain, so the reform narrows the national commitment when the evidence of provincial compensation capacity is thinnest.

Argentina Remediar Programme · Before Resolution 1447/2026

2023 2025
Treatments dispensed (IECS) 29.8 million 14.1 million

Source: IECS June 2026 report, cited by Perfil. The prior basket comprised 75 active ingredients in 99 presentations (IECS).

Why this is relevant

Patients

National deputy Pablo Yedlin warned, per Perfil, that medicines for children, adolescents, pregnant people and adults without cardiovascular disease fall outside national responsibility; the Instituto de Efectividad Clínica y Sanitaria (IECS) flagged that uneven provincial capacity could make treatment continuity depend on where a patient lives.

Industry

Generic manufacturers that supplied centralised Remediar tenders are likely to face provincial procurement processes with distinct budget cycles for the conditions that left the national list, which may be associated with higher transaction costs and less predictable volume.

Payers

Provincial health ministries inherit procurement for the conditions removed from the national list, with a transition kit through the end of 2026 as the only bridging mechanism announced by the federal ministry, per Perfil.

Regulators

The Ministerio de Salud de la Nación issued Resolution 1447/2026, repealing the 2021 essential medicines list approved by Resolution 3424/2021 and aligning national primary-care provision with the Plan Nacional de Salud Vascular 2026-2030.

Sources: Presidencia de la Nación: Resolución 1447/2026 — texto original · Perfil: El Plan Remediar cambia su foco y abre una disputa por el acceso a los medicamentos

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related